Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in a tax-free all-stock transaction to create a large CNS-focused biopharmaceutical company expected to generate $2.2 billion in combined annual revenue and $125 million in annual cost synergies. The combined entity will operate under the name Supernus, Inc. with Jack Khatta…